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Tubular iron deposition and iron 
handling proteins in human healthy 
kidney and chronic kidney disease
Sanne van Raaij1, Rachel van Swelm1, Karlijn Bouman1, Maaike Cliteur1, Marius van den 
Heuvel2,3, Jeanne Pertijs4, Dominic Patel5, Paul Bass6,7, Harry van Goor2, Robert Unwin6,8, 
Surjit Kaila Srai9 & Dorine Swinkels1
Iron is suggested to play a detrimental role in the progression of chronic kidney disease (CKD). The 
kidney recycles iron back into the circulation. However, the localization of proteins relevant for 
physiological tubular iron handling and their potential role in CKD remain unclear. We examined 
associations between iron deposition, expression of iron handling proteins and tubular injury in kidney 
biopsies from CKD patients and healthy controls using immunohistochemistry. Iron was deposited 
in proximal (PT) and distal tubules (DT) in 33% of CKD biopsies, predominantly in pathologies with 
glomerular dysfunction, but absent in controls. In healthy kidney, PT contained proteins required 
for iron recycling including putative iron importers ZIP8, ZIP14, DMT1, iron storage proteins L- and 
H-ferritin and iron exporter ferroportin, while DT only contained ZIP8, ZIP14, and DMT1. In CKD, iron 
deposition associated with increased intensity of iron importers (ZIP14, ZIP8), storage proteins (L-, 
H-ferritin), and/or decreased ferroportin abundance. This demonstrates that tubular iron accumulation 
may result from increased iron uptake and/or inadequate iron export. Iron deposition associated 
with oxidative injury as indicated by heme oxygenase-1 abundance. In conclusion, iron deposition is 
relatively common in CKD, and may result from altered molecular iron handling and may contribute to 
renal injury.
Chronic kidney disease (CKD) affects 13% of the population worldwide1. Current treatment for CKD patients is 
mainly aimed at ameliorating renal symptoms, including proteinuria2, a major risk factor for disease progression3. 
However, in many patients, this does not prevent progression to end-stage renal disease4. The absence of targeted 
treatment modalities can, at least partly, be attributed to the lack of detailed molecular knowledge on the patho-
physiological mechanisms of CKD.
Preclinical studies have suggested a detrimental role for (reactive) iron in the progression of CKD5. Increased 
exposure of renal tubular epithelial cells to iron leads to cellular damage6–9, since iron catalyzes highly reactive 
radical formation in the Fenton reaction10. In addition, in patients with various forms of CKD, increased urinary 
iron levels and renal iron deposition were found8,11–19, supporting an association between iron deposition and 
renal tubular injury. However, it has not been elucidated in which tubular segment iron is deposited.
Human-based studies examining renal iron handling are scarce5. It has been suggested that human renal 
tubular epithelial cells are able to handle iron in physiological conditions, but the localization of proteins involved 
in cellular iron handling is debated20. Transferrin-bound iron (TBI) in the systemic circulation is suggested to be 
filtered by the glomerulus into the tubular lumen21,22 and is subsequently completely reabsorbed by endocytic 
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transport20. This can be facilitated by transferrin receptor 1 (TfR1) and the megalin-cubilin receptor complex in 
proximal tubular epithelial cells (PT), and the NGAL receptor (NGALR) in distal tubular epithelial cells (DT)22–25. 
Based on in vitro and in vivo studies, iron transport into the cytosol is reported to involve the putative divalent 
metal transporters ZIP8 (SLC39A8), ZIP14 (SLC39A14) or divalent metal transporter 1 (DMT1, SLC11A2)26–28. 
Subsequently, iron is oxidized by the ferroxidase H-ferritin and stored in L-ferritin, utilized by iron requiring 
processes, or exported into the blood stream by iron exporter ferroportin (SLC40A1)20.
Proteinuria as a result of glomerular damage in CKD is linked to tubulointerstitial injury29, which is associated 
with increased filtration of TBI5,9,30. Increased exposure of TBI can lead to tubular accumulation of reactive iron 
as a result of inadequate or disturbed iron handling. In diabetic nephropathy, the kidney can also be exposed to 
non-transferrin-bound iron (NTBI) derived from filtered TBI as a result of acidification of the filtrate as it passes 
along the nephron5,31, or directly filtered from the circulation32. NTBI uptake from the tubular lumen is thought 
to be mediated by ZIP8, ZIP14 and/or DMT120.
For the first time in human kidney, we characterized associations between the presence and localization of 
iron deposition, proteins involved in cellular iron handling and tubular injury in kidney biopsies of patients with 
CKD and healthy controls.
Results
Iron deposition in CKD. We found iron deposition in 33% of biopsies from various forms of CKD (n = 126), 
but not in controls (n = 8; Fig. 1, Table 1). Iron was deposited in a granular pattern in tubular epithelial cells 
and in the majority of CKD in both PT and DT. In minimal change disease, iron deposition was found in PT 
Figure 1. Iron deposition in chronic kidney disease. Representative images of Perls’ staining in healthy 
control (a), diabetic nephropathy (b), membranous glomerulopathy (MG; c), IgA nephropathy (d), focal 
segmental glomerulosclerosis (FSGS; e), minimal change disease (f), lupus nephritis (g), Wegener’s disease (h), 
hypertension nephropathy (i), anti-glomerular basement membrane (GBM) disease (j), and thin basement 
membrane disease (TBMD; k). Renal structures indicated as glomerulus (G), proximal tubule (PT), distal 
tubule (DT). Iron indicated with arrows. Scale bar 20 µM.
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only. We detected iron deposition in kidney disorders characterized by nephrotic glomerulopathy (membra-
nous glomerulopathy, focal segmental glomerular sclerosis (FSGS), minimal change disease), glomerulonephri-
tis (Wegener’s disease, anti-glomerular basement membrane (GBM) disease), mesangial glomerular expansion 
(diabetic nephropathy), and potentially mixed nephrotic and nephritic glomerular injury (lupus nephritis (LN), 
IgA nephropathy (IgAN), hypertensive glomerulopathy) (Fig. 1b–k). These findings suggest that renal tubular 
iron deposition is a relatively common phenomenon in kidney disorders with glomerular dysfunction of different 
natures.
Tubular iron handling proteins in healthy kidney. In controls, ZIP8, ZIP14 and DMT1 were detected 
in both PT and DT (Fig. 2a–c, Table 2). ZIP8 was detected at the apical side of the tubules, whereas ZIP14 was 
localized intracellularly. DMT1 was observed both apically and intracellularly. Interestingly, L-ferritin, H-ferritin 
and ferroportin were observed only in PT (Fig. 2d–f, Table 2). Both ferritins showed intracellular orientation 
while ferroportin was expressed intracellularly and at the basolateral membrane. These findings indicate that PT 
express proteins for iron import, storage and export, while DT only express proteins involved in iron import in 
physiological conditions.
Tubular iron handling proteins in CKD. To characterize tubular iron handling during proteinuric CKD, 
a subset of kidney diseases was selected, including diabetic nephropathy, classified as early and advanced (DNE 
and DNA, respectively), FSGS, LN and IgAN (Table 3). Tubular localization of iron handling proteins in CKD 
was similar to controls (Figs 3–6). Staining intensity, however, differed between CKD and controls. ZIP14 showed 
comparable intensity in PT and DT, and, therefore, both segments were analyzed together. ZIP14 intensity was 
significantly increased in FSGS and IgAN compared to control (both p < 0.001; Fig. 3g–l,s). In FSGS, ZIP14 
intensity was increased in two patients only, while all IgAN biopsies showed enhanced ZIP14 staining. ZIP8 and 
DMT1 showed differential staining between PT and DT, and were, therefore, analyzed separately. ZIP8 intensity 
was increased in DT in DNE and FSGS compared to control (both p < 0.01; Fig. 3a–f,s), while ZIP8 intensity in 
PT (Fig. 3a–f,s) was unchanged. DMT1 intensity in either PT or DT was not different from control (Fig. 3m–r,s). 
L-ferritin staining was increased in FSGS (p < 0.001; Fig. 4a–f,m), mainly caused by 2 biopsies, while H-ferritin 
was overall increased in DNE (p < 0.05) and DNA (p < 0.001; Fig. 4g–l,m). Moreover, ferroportin showed 
decreased intensity in DNE (p < 0.01) and DNA (p < 0.001) in PT (Fig. 5). Interestingly, for some CKD biop-
sies, the observed changes in iron handling protein intensity coincided with iron deposition. In FSGS and IgAN 
biopsies with PT iron deposition, ZIP14 intensity was increased, which was accompanied by increased L-ferritin 
intensity in FSGS. In DNE and DNA with PT iron deposition, H-ferritin abundance was increased along with 
Kidney disease Abbreviation
Patients with tubular iron 
deposition/Total patients (n/n) (%)
Localization of 
iron deposition
Diabetic nephropathy DN 6/27 (22) PT + DT
Membranous glomerulopathy 7/21 (33) PT + DT
IgA nephropathy IgAN 7/19 (37) PT + DT
Focal segmental glomerular sclerosis FSGS 6/19 (32) PT + DT
Minimal change disease 3/13 (23) PT
Lupus nephritis LN 3/11 (27) PT + DT
Wegener’s disease 5/7 (71) PT + DT
Hypertension nephropathy 3/4 (75) PT + DT
Anti-glomerular basement membrane disease 1/1 (100) PT + DT
Thin basement membrane disease 0/1 (0)
Total 41/123 (33)
Healthy control 0/8 (0)
Table 1. Prevalence of tubular iron deposition in renal biopsies in chronic kidney disease. DT, distal tubule; PT, 
proximal tubule.
Protein
Proximal 
tubule
Distal 
tubule
Tubular localization
Apical Basolateral Intracellular
ZIP8 + + + − −
ZIP14 + + − − +
DMT1 + + + − +
L-ferritin + − − − +
H-ferritin + − − − +
Ferroportin + − − + +
Table 2. Tubular localization of iron handling proteins in the healthy kidney. DMT1, divalent metal transporter 
1; +, present; −, not detected.
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decreased ferroportin intensity. In DT, ZIP8 and/or ZIP14 were increased concurrent with iron deposition in 
DNE, FSGS and IgAN, but neither were observed in DNA. In contrast, no changes in protein abundance of both 
tubules were seen in any of the LN biopsies despite iron deposition in 2 of the biopsies. These findings are sum-
marized in Fig. 6.
Figure 2. Immunohistochemistry of iron handling proteins in healthy kidney. Representatives images of ZIP8 
(a), ZIP14 (b), divalent metal transporter 1 (DMT1; c), L-ferritin (d), H-ferritin (e), and ferroportin (f) staining 
in healthy kidney. Renal structures indicated as glomerulus (g), proximal tubule (PT), distal tubule (DT). Scale 
bar 20 µM.
Kidney disease Patients (n)
Age (years, 
mean ± SD) Gender (M/F)
Control 6 44.8 ± 16.1 3/3
DNE 8 46.6 ± 13.3 4/4
DNA 5 58.4 ± 12.4 4/1
FSGS 5 49.0 ± 18.3 3/2
LN 5 35.2 ± 14.2 1/4
IgAN 5 26.6 ± 9.2 3/2
Table 3. Characteristics of patients included for immunohistochemical staining of cellular iron handling 
proteins. DNE, established diabetic nephropathy; DNA, advanced diabetic nephropathy; F, female; FSGS, focal 
segmental glomerulosclerosis; IgAN, IgA nephropathy; LN, lupus nephritis; M, male. Biopsies selected based on 
tissue availability aiming at age- and gender-matched groups.
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In conclusion, our findings show associations between tubular iron deposition and abundance of iron han-
dling proteins in most types of CKD, which differ between specific pathologies. Overall, tubular iron deposi-
tion was related to increased iron import (ZIP8, ZIP14) in PT and DT, in some CKD biopsies accompanied by 
increased storage (ferritin) or decreased export (ferroportin) in PT.
Tubular injury in CKD. Tubular injury was assessed with PAS and heme oxygenase-1 (HO-1) staining. We 
used PAS staining to assess gross histology and scored renal injury based on tubular atrophy, blebbed tubular 
structures and irregular tubular cytoplasm (Fig. 7a–d). Renal damage was increased in DNE and DNA compared 
Figure 3. Immunohistochemistry of putative iron importers in chronic kidney disease. Representative 
images of ZIP8 (a–f), ZIP14 (g–l), and divalent metal transporter 1 (DMT1; m–r) staining in control (a,g,m), 
early diabetic nephropathy (DNE; b,h,n), advanced diabetic nephropathy (DNA; c,i,o), focal segmental 
glomerulosclerosis (FSGS; d,j,p), lupus nephritis (LN; e,k,q) and IgA nephropathy (IgAN; f,l,r). Intensity in 
proximal and distal tubules quantified (s). Dots represent all quantified images (5 images per biopsy). Renal 
structures indicated as glomerulus (G), proximal tubule (PT), distal tubule (DT). Scale bar 40 µM. **p < 0.01; 
***p < 0.001.
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to control and moderately elevated in FSGS (Fig. 7e). HO-1, a marker for oxidative cellular stress33, showed com-
parable intensity in both PT and DT, which was increased in CKD (control < DNE = DNA < IgAN < FSGS = LN; 
Fig. 8). Increased HO-1 staining coincided with iron deposition in DNE, FSGS, LN and IgAN, but was also 
induced in DT of DNA without iron deposition.
Figure 4. Immunohistochemistry of intracellular iron handling proteins in chronic kidney disease. Representative 
images of L-ferritin (a–f) and H-ferritin (g–l) staining in control (a,g), early diabetic nephropathy (DNE; b,h), 
advanced diabetic nephropathy (DNA; c,i), focal segmental glomerulosclerosis (FSGS; d,j), lupus nephritis (LN; 
e,k), and IgA nephropathy (IgAN; f,l). Intensity quantified (m) in proximal tubules. Dots represent all quantified 
images (5 images per biopsy). Renal structures indicated as glomerulus (G), proximal tubule (PT), distal tubule 
(DT). Scale bar 40 µM. *p < 0.05; ***p < 0.001.
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In conclusion, we found oxidative cellular stress, but not histological damage, to associate with iron deposition.
Discussion
Increased iron accumulation may be a detrimental factor in progression of CKD, but the mechanisms of iron handling 
in the human kidney are not fully elucidated. In this study we found iron deposition in one third of biopsies from 
various CKD disorders, predominantly in pathologies with glomerular dysfunction. We observed that in the healthy 
Figure 5. Immunohistochemistry of cellular iron export protein in chronic kidney disease. Representative 
images of ferroportin staining in control (a), early diabetic nephropathy (DNE; b), advanced diabetic 
nephropathy (DNA; c), focal segmental glomerulosclerosis (FSGS; d), lupus nephritis (LN; e), and IgA 
nephropathy (IgAN; f). Intensity quantified (g) in proximal tubules. Dots represent all quantified images (5 
images per biopsy). Renal structures indicated as glomerulus (G), proximal tubule (PT), distal tubule (DT). 
Scale bar 40 µM. **p < 0.01; ***p < 0.001.
www.nature.com/scientificreports/
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kidney, PT contain proteins involved in iron import, storage and export, while DT only showed proteins involved in 
iron import. Associations between iron deposition, intensity of iron handling proteins and tubular injury in CKD were 
seen, which differed between the pathologies. Nevertheless, in the majority of CKD, tubular iron deposition was accom-
panied by an increase in iron import proteins ZIP8 and/or ZIP14 in both PT and DT. This coincided with an increase 
in iron storage proteins or decrease in iron exporter in PT and increased oxidative cellular injury in both PT and DT.
Our data show that iron deposition is a relatively common phenomenon in CKD with glomerular dysfunc-
tion. In physiological conditions, TBI filtered by the glomerulus is believed to be almost completely reabsorbed 
by the tubular epithelium. In this process, PT reabsorb the bulk of filtered proteins and DT play only a minor 
role20. We hypothesize that in nephropathic glomerulopathy or pathologies with mesangial glomerular damage, 
PT iron reabsorption is increased by large amounts of TBI leaking from the injured glomerulus, resulting in local 
iron deposition. Moreover, when the reabsorption capacity of PT is overwhelmed, DT might also be exposed 
to increased iron levels, leading to DT iron deposition. In addition, we found iron deposition in pathologies 
with nephritic glomerular damage, which present with both hematuria and proteinuria34. Our results comple-
ment previous studies of renal iron deposition in CKD biopsies11,12, which was localized to PT lysosomes18,19. 
In our study, we demonstrated iron deposition also in DT in CKD. In addition, we show that iron deposition 
relates to oxidative cellular injury, as assessed by HO-1 staining. This strengthens the supposition that iron accu-
mulation facilitates highly reactive radical formation that damage membranes, proteins and DNA, and, subse-
quently, causes tissue injury, which has been reported in renal tubular cells and animal models of CKD6–9,35–37. 
Interestingly, iron reduction via a low-iron diet or treatment with an iron chelator has been reported to reduce 
renal iron accumulation and tubulointerstitial injury in various CKD animal models35–37. Together with findings 
of increased urinary iron levels and renal iron deposition in patients with CKD11–19, this suggests that renal iron 
loading could contribute to disease progression in patients with CKD. Biopsies used in this study were taken 
for diagnostic purposes and are usually at a relatively early stage in disease progression, which is reflected by 
their tubular injury score. However, renal injury was already more established at the time of biopsy for diabetic 
nephropathy, especially for DNA. Nevertheless, our findings of iron deposition and associated oxidative cellular 
injury in FSGS, LN and IgAN biopsies suggest that iron may already be involved in the onset of renal disease and 
contribute to CKD progression.
We are the first to show ZIP14 and DMT1 in human kidney, whereas ZIP8 was previously described in human 
kidney38. Until now, DMT1 and ZIP14 were only demonstrated in murine PT, and DMT1 and ZIP8 in only 
mouse and rat DT39–45. Luminal TBI reabsorption is suggested to involve TfR1, but TfR1 localization, on the api-
cal or basolateral membrane of tubular epithelial cells, is debated31,41,46–48. Since we did not obtain reliable TfR1 
stainings, our study is not able to add to the understanding of TfR1 localization. Following entry in the cytosol, 
iron is known to be oxidized by H-ferritin and stored in L-ferritin. Our results of intracellular expression of both 
ferritins in PT agree with other studies48,49. Cytosolic iron is suggested to be transported back to the systemic 
circulation via the exporter ferroportin20. Although both apical and basolateral localization of ferroportin are 
shown in murine PT31,41,46–48, our human kidney results clearly demonstrate basolateral localization only. This 
discrepancy might be related to species difference50. In our studies, ferroportin was absent in DT, as is shown in 
rats46. The absence of ferritin and ferroportin in DT support that DT only play a minor role in physiological TBI 
Figure 6. Overview of observations on iron deposition and intensity of iron handling proteins in chronic 
kidney disease. Overview of iron deposition (in blue) and iron handling protein intensity in healthy control 
(a), early diabetic nephropathy (DNE; b), advanced diabetic nephropathy (DNA; c), focal segmental 
glomerulosclerosis (FSGS; d), lupus nephritis (LN; e), and IgA nephropathy (IgAN; f ). Increased protein 
intensity compared to healthy controls (in grey) visualized in green, decreased protein intensity in red. DMT1, 
divalent metal transporter 1.
www.nature.com/scientificreports/
9SCIENTIFIC REPORTS |  (2018) 8:9353  | DOI:10.1038/s41598-018-27107-8
reabsorption. Lack of effective iron storage and export could make these cells vulnerable to iron accumulation 
and related injury in case of high iron exposure.
For the majority of CKD disorders, we could distinguish an overall increased intensity of ZIP8 or ZIP14 that 
might have contributed to iron deposition. TfR1 and DMT1 are known to protect cells by limiting iron uptake via 
iron responsive element-iron responsive protein (IRE-IRP) regulation51, but this is not described for ZIP8 and 
ZIP1452. Interestingly, ZIP8 and ZIP14 increase with iron loading in hepatocytes28,53. Therefore, ZIP8 and ZIP14 
are plausible candidates for unrestricted iron import and subsequent iron loading in kidney tubular epithelium 
from either endocytosis TBI or direct NTBI transport over the apical membrane5,31,32. Future assessment of the 
intracellular localization and function of ZIP8 and ZIP14 would be valuable to dissect potential iron transport 
routes in CKD.
We observed decreased ferroportin and concomitant increased H-ferritin intensity in diabetic nephropathy, 
which may explain PT iron deposition in these patients. Based on IRE-IRP regulation, however, we would expect 
ferroportin to increase with cellular iron loading51. At the systemic level, ferroportin is regulated by hepcidin, 
which causes ferroportin degradation54. Also renal ferroportin protein abundance is shown to decrease with high 
circulating hepcidin levels55. Interestingly, elevated hepcidin levels have been reported in patients with type 2 
diabetes in the presence of chronic renal disease, obesity or inflammation56,57, which could explain the observed 
reduction in ferroportin intensity. Unfortunately, serum hepcidin levels were not available in our study. Moreover, 
Figure 7. PAS staining for tubular injury in chronic kidney disease. Representative images of PAS staining in 
control (a) or chronic kidney disease showing atrophic tubules with loss of brush border and enlarged basement 
membrane (b), blebbed tubules (c) and interstitial fibrosis (d). Percentage of tissue with tubular injury scored 
(E) per patient. Renal structures indicated as glomerulus (G), proximal tubule (PT), and distal tubule (DT). 
Symbols indicate proximal tubular brush border with asterisk, blebbed tubules with double asterisk, basement 
membrane with arrow, and fibrosis with hashtag. Scale bar 20 µM.
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renal biopsies in our study were obtained from patients with either type 1 or type 2 diabetes and the former 
patients do not have increased hepcidin levels58. Our findings of an association between decreased ferropor-
tin and increased H-ferritin are corroborated by studies in human macrophages in which ferroportin silencing 
led to increased H-ferritin protein levels59, suggesting that H-ferritin upregulation could result from decreased 
ferroportin. Conversely, others showed a reciprocal relationship between H-ferritin and ferroportin by report-
ing reduced ferroportin mRNA and protein levels in conditional PT H-ferritin knockout mice48. Ferroportin is 
regulated by several multilayered signals, where hepcidin is reported to have a dominant effect54. This makes it 
difficult to determine whether renal iron deposition is due to ferroportin decreases or merely results from other 
mechanisms. Moreover, because of its multilayered regulation, the contribution of ferroportin to tubular iron 
loading may be different for various kidney diseases as observed in our study.
Besides ferroportin, also other cellular proteins involved in renal iron handling are regulated by processes 
beyond iron metabolism, including inflammation and oxidative stress54,60,61. These processes are also believed 
to contribute to the pathophysiology of CKD62. Therefore, changes in abundance of proteins we studied cannot 
solely be attributed to changes in iron handling. Vice versa, iron loading was observed in LN without changes in 
protein abundance. In these patients, iron accumulation could be mediated by other potential iron transporters 
that we were not able to include in this study, such as TfR1, the megalin-cubilin receptor complex or NGALR22–
25. This underlines the complex mechanisms involved in the various CKD pathologies, which may (to various 
extents) all contribute to changes in renal iron handling proteins.
Figure 8. Immunohistochemistry of injury marker HO-1 in chronic kidney disease. Representative images 
of heme oxygenase-1 (HO-1) staining in control (a), early diabetic nephropathy (DNE; b), advanced diabetic 
nephropathy (DNA; c), focal segmental glomerulosclerosis (FSGS; d), lupus nephritis (LN; e), and IgA 
nephropathy (IgAN; f). Renal structures indicated as glomerulus (G), proximal tubule (PT), and distal tubule 
(DT). Scale bar 40 µM.
www.nature.com/scientificreports/
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In summary, our findings in human renal biopsies form the basis for further elucidating renal iron handling in 
health and disease. Future studies should focus on unraveling the molecular mechanisms of renal iron loading in 
individual CKD disorders. This will determine whether and how reduction of renal iron accumulation in CKD is 
a feasible target to halt disease progression.
Methods
Design. Biopsies from patients with CKD and controls were used to examine the presence and localization 
of iron deposition. Subsequently, a selection of prevalent kidney diseases63 and controls was made to examine 
proteins involved in cellular iron handling and tubular injury.
Patients. Renal biopsy material was collected from patients with CKD and potential kidney donors (healthy 
controls). Biopsies were classified based on clinical presentation of the patient and histological assessment by 
a trained renal pathologist. Biopsies were collected in University Medical Centre Groningen (the Netherlands 
(NL)) and Royal Free Hospital (RFH; London, United Kingdom (UK)), during the period of 1996–2014 and 
2011–2016, respectively. Biopsies from both hospitals were used to assess iron deposition. For assessment of iron 
handling proteins and tubular injury, CKD biopsies and healthy kidneys from RFH only were selected, based on 
tissue availability aiming at age- and gender-matching. Biopsies with excessive tissue damage ( >70% of tissue) 
were excluded.
Procedures and use of anonymized material left over from diagnostic care were performed according to Dutch 
ethical guidelines. Accordingly, this study did not require approval from an ethical committee and material from 
patients from UMCG could be used without informed consent. All patients from RFH signed informed consent. 
All material was collected according to the Declaration of Helsinki.
Histological stainings. Biopsy tissue was embedded in paraffin and cut into 5 µm sections. Renal histology 
was assessed by Periodic acid-Schiff (PAS) staining and iron deposition by Perls’ staining, according to routine 
staining protocols.
Immunohistochemistry. Stainings were performed using the Bond Polymer Refine Detection system (Leica 
Biosystems, Newcastle-Upon-Tyne, UK) and provided materials on a Leica Bond Max and Autostainer XL appa-
ratus for DMT1 (Novus Biologicals, Abingdon, UK, H00004891-M01, 1:2000), ZIP8 (Protein Tech, Manchester, 
UK, 20459-1-AP, 1:500), ZIP14 (Atlas Antibodies, Bromma, Sweden, HPA016508, 1:1000), L-ferritin (Abcam, 
Cambridge, UK, ab69090, 1:2000), H-ferritin (Abcam ab65080, 1:4000), ferroportin (Abcam ab85370, 1:300) and 
HO-1 (Abcam ab13243, 1:100). After antigen retrieval (Bond ER1 or ER2), sections were incubated with primary 
antibody for 15 min diluted in Bond Primary Antibody diluent or Antibody diluent with Background Reducing 
Components (Dako Agilent, Stockport, UK) and secondary antibody for 8 min. Signal visualization was per-
formed with Polymer Refine for 8 min, DAB for 10 min and DAB enhancer (Leica Biosystems). Afterwards, nuclei 
were counterstained with haematoxylin and images were taken with a Leica DM 2000 microscope connected to a 
Leica Microsystem Ltd camera, NanoZoomer whole slide imager (Hamamatsu Photonics, Welwyn Garden City, 
UK) or a VisionTek digital microscope (Sakura Finetek, Alphen aan den Rijn, NL). Appropriate negative control 
stainings were included for all primary and secondary antibodies (Supplementary Figure 1 and 2, respectively).
Image analysis. Stainings were evaluated by an expert in renal pathology. Staining intensity was assessed in 
5 images per biopsy using the H DAB plugin of ImageJ after correction for background staining. Tubular injury 
was scored as percentage of the kidney section.
Statistical analysis. Data were analyzed by one-way ANOVA with Dunnett’s post test using GraphPad 
Prism, to evaluate staining intensity and tubular injury in CKD compared to control. Differences were considered 
statistically significant when p < 0.05.
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